Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1-Reference-Cited by-同舟云学术

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Published:2015-11-20 Issue:6263 Volume:350 Page:972-978
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Vacchelli Erika¹²³⁴⁵,Ma Yuting¹²³⁴⁵,Baracco Elisa E.¹²³⁶,Sistigu Antonella⁷,Enot David P.¹²³⁸,Pietrocola Federico¹²³⁶,Yang Heng¹²³⁴⁵,Adjemian Sandy¹²³,Chaba Kariman¹²³⁴,Semeraro Michaela¹⁹¹⁰,Signore Michele¹¹,De Ninno Adele¹²,Lucarini Valeria¹¹,Peschiaroli Francesca¹¹,Businaro Luca¹²,Gerardino Annamaria¹²,Manic Gwenola⁷,Ulas Thomas¹³,Günther Patrick¹³,Schultze Joachim L.¹³,Kepp Oliver¹²³⁴⁵,Stoll Gautier¹²³⁴⁵,Lefebvre Céline¹¹⁴,Mulot Claire¹⁵¹⁶,Castoldi Francesca¹²³⁶¹⁷,Rusakiewicz Sylvie¹⁹¹⁰,Ladoire Sylvain¹⁸¹⁹²⁰,Apetoh Lionel¹⁸¹⁹²⁰,Bravo-San Pedro José Manuel¹²³⁴⁵,Lucattelli Monica²¹,Delarasse Cécile²²,Boige Valérie¹⁶²³,Ducreux Michel⁶²³,Delaloge Suzette¹⁴²⁴,Borg Christophe²⁵,André Fabrice¹¹⁴²⁶²⁷,Schiavoni Giovanna¹¹,Vitale Ilio⁷²⁸,Laurent-Puig Pierre¹⁵¹⁶²⁹,Mattei Fabrizio¹¹,Zitvogel Laurence¹⁶⁹¹⁰,Kroemer Guido¹²³⁴⁵

Affiliation:

1. Gustave Roussy Cancer Campus, Villejuif, France.

2. INSERM, U1138, Paris, France.

3. Équipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.

4. Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

5. Université Pierre et Marie Curie, Paris, France.

6. Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France.

7. Regina Elena National Cancer Institute, Rome, Italy.

8. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.

9. INSERM, U1015, Villejuif, France.

10. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.

11. Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

12. Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.

13. Genomics and Immunoregulation, Life and Medical Science Center Institute, University of Bonn, Germany.

14. INSERM, U981, Villejuif, France.

15. Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.

16. INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France.

17. Sotio, Prague, Czech Republic.

18. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

19. Université Bourgogne Franche-Comté, Dijon, France.

20. Centre Georges François Leclerc, Dijon, France.

21. Department of Life Sciences, University of Siena, Siena, Italy.

22. Institut du Cerveau et de la Moelle Épinière, ICM CNRS UMR 7225 – INSERM U 1127 – UPMC-P6 UMR S 1127, Équipe Neurogénétique et Physiologie Hôpital de la Pitié-Salpêtrière, 47, Boulevard de l’Hôpital, 75013 Paris, France.

23. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, France.

24. Department of Breast Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

25. University of Franche-Comté, INSERM 1098, France.

26. Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.

27. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

28. Department of Biology, University of Rome “Tor Vergata,” Rome, Italy.

29. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Abstract

How dying tumor cells get noticed Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference40 articles.

1. Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

2. Lymphocytes prognostic in breast cancer

3. Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

4. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

5. Trial watch

Cited by 379 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of tumour environments through advancements in microtechnology and nanotechnology;Biomedicine & Pharmacotherapy;2024-09

2. Reprogramming Tumor Microenvironment with Precise Photothermal Therapy by Calreticulin Nanobody-Engineered Probiotics;Biomaterials;2024-09

3. Dihydroartemisinin restores the immunogenicity and enhances the anticancer immunosurveillance of cisplatin by activating the PERK/eIF2α pathway;Cell & Bioscience;2024-08-01

4. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

5. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination;Cancer Letters;2024-08